Brief Report

POTENTIAL ROLE OF APRIL AS AUTOCRINE GROWTH FACTOR FOR MEGAKARYOCYTOPOIESIS

Désirée Bonci, Michael Hahne, Nadia Felli, Cesare Peschle, Ruggero De Maria

Laboratory of Hematology and Oncology, Istituto Superiore di Sanità, Rome 00161, Italy
Institut de Génétique Moléculaire de Montpellier, UMR 5535/CNRS, 34293 Montpellier, France
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Mediterranean Institute of Oncology, 95029 Catania, Italy

Correspondence: Dr. Ruggero De Maria, Department of Hematology and Oncology, Viale Regina Elena 299, 00161 Rome, Italy. Telephone: +39 0649903121, Fax: +390649387087, e-mail: rdemaria@tin.it.

Scientific Heading: Hematopoiesis

Running Title: APRIL promotes megakaryocytopenesis

Footnotes: Supported by funding from the Italian Association for Cancer Research (A.I.R.C.) and Association of International Cancer research (A.I.C.R.).
ABSTRACT

A Proliferation Inducing Ligand (APRIL) is a new tumor necrosis factor family member implicated in tumor cell proliferation. We investigated the role of APRIL in megakaryocytopoiesis, a developmental hematopoietic process responsible for progenitor cell differentiation to megakaryoblasts and megakaryocytes, leading to platelet formation. APRIL is not expressed in CD34+ progenitor cells from normal donors, but it is massively upregulated during the proliferative phase of megakaryocytic cell differentiation. Exogenous APRIL expression in primary cells increases megakaryocytic cell growth, suggesting that APRIL acts as a proliferative factor in megakaryocytopoiesis. More importantly, neutralization of endogenous APRIL was able to dramatically reduce megakaryocyte expansion and platelet production. Thus, our data provide evidence that APRIL acts as a growth factor for terminal megakaryocytopoiesis and may promote physiological platelet production.
INTRODUCTION

The production of mature megakaryocytes (MKs) from multipotent hematopoietic progenitor cells requires the coordinated activity of different cytokine signaling pathways to assure controlled cell proliferation, survival and differentiation.\textsuperscript{1-3}

Thrombopoietin (TPO) is a major hematopoietic growth factor that supports early hematopoietic cells and all the developmental stages of megakaryocytopoiesis.\textsuperscript{4,5} Several other cytokines can promote MK growth and platelet production in physiological or pathological circumstances, including stem cell factor, IL-1, IL-3, IL-6 and IL-11.\textsuperscript{1,2} Increased platelet production is observed in essential thrombocytopenia and during inflammation, as the inflammatory environment promotes the formation of MKs\textsuperscript{2}. The tumor necrosis factor (TNF) family is a group of cytokines involved in the regulation of cell death, proliferation, activation and differentiation. Some members of the TNF family bind and activate death receptors, a group of surface proteins able to transduce apoptotic signals upon ligand binding.\textsuperscript{6-8} Death receptor ligands are likely to inhibit the megakaryopoietic process, as shown by the ability of CD95 (Fas/APO-1) ligand to block megakaryocyte maturation through the specific targeting of key developmental transcription factors.\textsuperscript{9} Recently, A Proliferation Inducing Ligand (APRIL) has been identified as a new member of the TNF family proteolytically processed in the Golgi compartment by a furin convertase and released as a soluble form.\textsuperscript{10,11} Furin is involved in the maturation of growth factors and integrins synthesized by MKs, and appears as a key enzyme for megakaryocytopoiesis and thrombocytopoiesis.\textsuperscript{12,13} APRIL mRNA levels are reportedly low in normal tissues. In contrast, high mRNA levels have been detected in tumor cell lines and in several primary tumor tissues.\textsuperscript{14-16} Such expression has been proposed to promote cancer cell survival and proliferation, as exogenous expression of APRIL increased tumor cell growth in vitro and in vivo.\textsuperscript{10} Although APRIL can bind to BCMA and TACI receptors, the pro-tumor effect of this cytokine seems mediated by at least one additional, yet unidentified, receptor.\textsuperscript{15} Similarly, recent evidence supports the presence of a functional receptor, different from BCMA and TACI, in fibroblast and epithelial cell lines.\textsuperscript{10,15} The existence of another functional receptor is further corroborated by the inability of Bls/BAFF, another member of the TNF family capable of binding BCMA and TACI, to promote the proliferation of APRIL-sensitive tumor cells.\textsuperscript{14,15,17}

We speculate that the ability of APRIL to act as autocrine growth factor was not confined to tumor cells. Therefore we investigate APRIL expression and function in hematopoiesis. Here, we show that
MKs express considerable levels of APRIL and that targeting endogenous APRIL production severely affects MK proliferation and platelet generation.

STUDY DESIGN

Cell cultures and gene transfer studies

CD34+ cells were purified from cord blood samples by ficoll gradient centrifugation and three rounds of microbeads sorting (Miltenyi Biotec, GmbH, Germany). Megakaryocytic unilineage cultures were obtained by cultivating CD34+ cells in serum free medium supplemented with 100ng/ml TPO. Platelet production was evaluated as previously described.

APRIL and BLyS cDNAs were cloned into the retroviral vector, PINCO-GFP (green fluorescent protein). CD34+ cells were subjected to six infection cycles and placed in growth medium supplemented with cycling growth factors (IL-3 100U/ml, SCF 100ng/ml, Flt3 100ng/ml) for 48 hours before sorting. GFP-positive cells were separated by flow cytometry and cultivated in serum-free medium containing 100ng/ml TPO to obtain virtually pure transduced MK populations.

RT PCR and immunoblot analysis

cDNA amplification was obtained by 35 PCR cycles. PCR products were verified by sequencing, analyzed by Southern blotting and normalized by amplification of the S26 gene. APRIL forward primer: 5’TAAAAAAGTGGCCTCCCAGCTT3’; reverse primer 5’GGTGCGGAATGAAAAGGGAAA3’; probe: 5’CATCTTCCTGGGTGTTGGCTCCCCCGTTCCTC3’. BCMA forward primer: 5’TTTCTTTGCGAGTTTTCGTG3’; reverse primer: 5’GATGCGAGTCTTCACAGGTGC3’; probe: 5’GGTCCTCTGGGCATGGCTAACATTGACCTG3’. TACI forward primer: 5’CCAAGGATTTGGACACAGA3’; reverse primer: 5’GGCAGGACACACACACAAT3’; probe: 5’GCCCGCCTCAAGGCCCCGCTCAGGACTCAGCCGC3’.

Real-time RT-PCR was performed by TaqMan technology, using ABI PRISM 7700 DNA Sequence Detection System (Applied Biosystems, Foster City, CA). Thermal cycling conditions included 40 cycles at 95°C for 15 s and at 60°C for 1 min. Original input RNA amounts were calculated with relative standard curves for APRIL and GAPDH RNA. Gene expression values were reported as the normalized percentage derived by dividing the copy numbers of APRIL by GAPDH, using cells transduced with APRIL cDNA as reference control. Commercial ready to use primers/probe mixes
were used (Assay-on-Demand Gene Expression products, Hs00601664_g1, Applied Biosystems).

Protein extracts were prepared by resuspending cell pellets in 1% NP40 lysis buffer. Equal amounts of proteins were analyzed by standard immunoblot procedure. The rabbit polyclonal anti-APRIL antibody was produced as previously described, and used at 5 \( \mu g/ml \). Anti-BLyS polyclonal rabbit antibody (BD PharMingen, Los Angeles, CA) was used at dilution of 1:1000.

Cell surface binding of APRIL was assessed by incubating 2x10^5 cells with 100ng/ml of Flag-APRIL (APRIL MEGA Ligand; Alexis, Lausen, Switzerland) for 1h at 37°C. After incubation, cells were washed three times in PBS and APRIL receptor expression was evaluated by immunofluorescence staining using anti-Flag-M2 (by SIGMA, St. Louis, MO) and a FITC-conjugated anti-mouse (Molecular Probes, Eugene, OR).

RESULTS AND DISCUSSION

The megakaryocytic unilineage liquid culture system recapitulates physiological megakaryocytopoiesis and allows the study of different steps of the differentiation process.

In TPO-supplemented culture of cord blood CD34^+ cells, morphological evaluation indicates the presence of putative mononuclear megakaryoblasts at day 2-3, then at day 10-12 cells mature in binuclear and polynucleated MKs and begin to produce platelets.

We analyzed megakaryocytic cells at various differentiation stages for the expression of APRIL and its receptors. Flow cytometry analysis showed that APRIL binding to its putative receptors was absent in CD34^+ cells, but gradually increased during MK differentiation (Fig. 1A). Similarly, APRIL mRNA was not present in CD34^+ cells or in day 3 megakaryoblasts, but was easily detectable from day 5 until the end of the culture, reaching considerably high levels around day 9 (Fig. 1B and C). Moreover, immunoblot analysis revealed the presence of both full-length and soluble APRIL in MKs (Fig. 1D). In contrast, we were not able to detect TACI or BCMA mRNA at any stage of megakaryocytic differentiation (Fig. 1B), suggesting that APRIL binding to MKs depends on the presence of a different receptor.

The expression of APRIL in megakaryoblasts prompted us to investigate whether APRIL could influence the growth of megakaryocytic cultures. We therefore transduced cord blood CD34^+ progenitor cells with a retrovirus carrying the APRIL cDNA and GFP as reporter gene, so that the positive cells could be sorted by FACS. Both the empty vector and a vector containing the cDNA of BLYS/BAFF were transduced as negative controls. Expression of exogenous genes in GFP^+ cells was
confirmed by immunoblot analysis (Fig. 2A). Sorted cells were cultivated in MK unilineage medium for 8 days, as the previous exposure to the cycling factors during retroviral transduction reduces the time required for the complete maturation of hematopoietic precursors.\textsuperscript{9} Megakaryocytic culture quantification revealed a significant increased expansion of APRIL-transduced cells during the proliferative phase as compared with the control populations, while during late differentiation period the differentially transduced cells showed a comparable modest increase in number (Fig. 2B). Thus, exogenous APRIL promotes the growth of megakaryocytic cells during their expansion phase.

To determine whether the production of endogenous APRIL contributes to the megakaryopoietic process, cord blood CD34\textsuperscript{+} cells were grown in MK unilineage culture in the presence of soluble human recombinant TACI:Fc fusion protein, which binds APRIL and neutralizes its proliferative activity. As shown in Fig. 2C, exposure to TACI:Fc fusion protein dramatically reduced the growth of megakaryocytic cells, while the Fn14:Fc fusion protein that interacts with TWEAK, another member of the TNF family, was ineffective. Similarly, the addition of TACI:Fc fusion protein in the culture medium from day 5 resulted in a significant decrease of platelet production (Fig. 2D), confirming the contribution of autocrine APRIL production to megakaryocytopoiesis. Upon exposure to TACI:Fc, we did not observe a significant increase in apoptosis, nor a decreased production of platelets per single megakaryocyte (results not shown). Thus, the contribution of APRIL on megakaryocytopoiesis seems to be the result of a direct increase in MK proliferation.

Data presented here indicate that APRIL acts as an autocrine growth factor for megakaryocytic cells. During in vitro differentiation, APRIL is expressed from the promegakaryocytic stage until terminal maturation. The strong reductions of MK growth and platelet production obtained after neutralization of endogenous activity suggest that APRIL may promote the physiological megakaryocytopoiesis.

Although original reports have focused their attention on the role of APRIL in tumorigenesis, APRIL expression has been found in monocytes and dendritic cells.\textsuperscript{21,22} Moreover, recent data indicate that APRIL modulates B and T cell immunity,\textsuperscript{14,22,23} suggesting that APRIL may act on different hematopoietic cells.

BCMA and TACI expression appears to be restricted to B lymphocytes. Accordingly, no expression of TACI or BCMA could be detected in megakaryocytes. Therefore, we conclude that APRIL binding and growth signaling in megakaryocytes are mediated by another unknown receptor, as supposed by different authors in other systems.\textsuperscript{15,17} Different cytokines can increase MK growth and
platelet production in concert with TPO. These pro-megakaryocytic factors are generally produced by other cell types, such as leukocytes, fibroblasts and bone marrow stroma cells. However, megakaryocytes can produce cytokines that promote their differentiation program, such as platelet-derived growth factor and von Willebrand factor. Moreover, we have recently shown that autocrine-paracrine VEGF loops can increase MK polyploidization through the stimulation of Flt1 receptor. The ability of endogenous APRIL to contribute to MK expansion suggests that it can constitute a major autocrine growth factor for megakaryocytosis. Thus, it is likely that the activity of self-produced cytokines is not restricted to the accomplishment of the MK differentiation program, but may play a considerable role in MK growth, eventually contributing to determine the amount of platelet production.

ACKNOWLEDGMENTS
Authors thank Paola Di Matteo, Stefano Guida, Gualtiero Mariani and Giuseppe Loreto for their contribution to the paper.
REFERENCES

7. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66


19. Mattia G, Vulcano F, Milazzo L, Barca A, Macioce G, Giampaolo A, Hassan HJ. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood. 2002;99:888-897


E, Morsilli O, Gabbianelli M, Testa U, Peschle C. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101:1316-1323
FIGURE LEGENDS

**Fig. 1 Expression of APRIL and its receptors during MK differentiation.**

A) Flow cytometry analysis of cord blood CD34+ cells undergoing unilineage MK differentiation (from day 3 to day 14) labeled with recombinant Flag-APRIL (open histograms) as compared with staining controls (black histograms). Jurkat and 293 cells were used as positive and negative controls, respectively. B-C) Semiquantitative RT-PCR (B) and real-time (C) analyses of CD34+ and differentiating megakaryocytic cells. Peripheral blood mononuclear cells (PBMC) and hematopoietic progenitors transduced with empty vector (PINCO) or with APRIL cDNA (APRIL) were used as controls. D) Immunoblot analysis of APRIL expression in CD34+ and differentiating megakaryocytic cells. 293 cells transfected with empty vector (P) or with APRIL cDNA (APRIL) were used as controls.

**Fig. 2 APRIL promotes megakaryocyte expansion and platelet production.**

A) Cycling cord blood CD34+ cells were transduced with empty vector (P), with APRIL (APRIL) or BLyS (BLyS) cDNA and analyzed by immunoblot for APRIL and BLyS expression after cytofluorimetric sorting based of GFP+ cells. 293 cells transfected with empty vector (P), or with APRIL (APRIL) or BLyS (BLyS) cDNA were used as controls. B) Cell growth of cells transduced and sorted as in A and cultured in unilineage MK system from day 0 to day 3 and from day 5 to day 8. C) Cell growth of cord blood CD34+ cells cultured in standard unilineage MK system (Control) or in the presence of TACI:Fc or Fn14:Fc recombinant soluble proteins (Alexis, San Diego, CA). D) Platelet production from unilineage MK culture or in the presence or in the absence of recombinant soluble TACI:Fc.
FIG. 2

A. Western blot analysis of APRIL and sAPRIL in HPC and 293 cells. APRIL shows bands at 30Kd and 21.5Kd.

B. Graph showing cell growth (% increase over input) over days 0-3 and 5-8. P, APRIL, and BLyS show different growth patterns.

C. Cell number growth over days 0-14. Control, FN14-Fc, and TACI-Fc show different growth kinetics.

D. Platelet number (x10^9) over days 9, 12, and 14. Control, and TACI-Fc show different platelet counts.

FIG. 2
Potential role of APRIL as autocrine growth factor for megakaryocytogenesis

Desiree Bonci, Michael Hahne, Nadia Felli, Cesare Peschle and Ruggero De Maria